Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Dec

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Alkylating Agent-Based Treatment in Neuroendocrine Tumors According to MGMT Status

De-escalated Neoadjuvant Combination Therapy for HER2-Positive Early Breast Cancer

Potential Cancer Vaccine Target Uncovered in E coli Bacteria

Prior Authorization Delays May Lead to Severe Consequences for Patients With Cancer

FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma